HealthCare.com® Extends Previously Announced $180M Financing with Additional $31.5M Investment from Hildred Capital
NEW YORK & MIAMI–(BUSINESS WIRE)–HealthCare.com, a leading data-driven insurtech platform, announced today the extension of its recent Series C equity round, which was led by Oaktree Capital Management, L.P. (“Oaktree”) as well as existing investors AXIS Capital, Second Alpha and Link Ventures. The additional $31.5M in Series C equity financing came from healthcare-focused private equity firm Hildred Capital Management (“Hildred”), bringing the total funding round to $211.5M.
PlasmaSaves.Org Donates $20,000 to God’s Love We Deliver
Second Alpha Partners sponsor PlasmaSaves.org, an organization founded during COVID-19 to facilitate the collection of plasma to save lives, is thrilled to announce a $20,000 donation to God’s Love We Deliver.
Apis Growth Fund II invests US$50 million Series C in Giift, a Global Leader in Loyalty Program Management
Apis Growth Fund II, a private equity fund managed by Apis Partners LLP, a UK-based asset manager that supports growth stage financial services and financial infrastructure businesses, has invested US$50 million in Giift, the global leader in loyalty program management and development. Apis Growth Fund II was the sole investor in the Series C round.
Prove Ranked as Identity Verification Leader by G2 Users
“We are humbled to be acknowledged as a top leader by G2, a ranking from customers and users of our product, showcasing the value and power of Prove’s platform, innovation, and commitment as a leader in the digital identity space,” said Rodger Desai, Co-Founder and CEO of Prove. “Prove is on a mission to deliver digital trust, allowing businesses to garner the confidence to do more in the digital-first world that continues to evolve.
23andMe gets FDA clearance for prostate cancer risk test
Genetics testing company 23andMe received Food and Drug Administration clearance for its prostate cancer risk test, the company announced today. It’s 23andMe’s third clearance for a cancer risk report — the company also has tests for genes that predict breast and colorectal cancer risk.
23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-00610 for the treatment of advanced solid tumors.
DAILYPAY ANNOUNCES ITS DIGITAL WALLET SOLUTION TO HELP WORKERS STAY FINANCIALLY STABLE
DailyPay, featured in TIME’s “Best Inventions of 2021,” today announced their one-of-a-kind digital wallet solution. DailyPay’s digital wallet solution is designed for everyday working Americans, many of whom are facing unprecedented financial challenges with the resurgence of the pandemic.
HealthCare.com® Raises $180 Million in Oversubscribed Financing Round Led by Oaktree
HealthCare.com, a leading data-driven insurtech platform, announced today the closing of $130 million in Senior Non-Convertible Preferred and more than $50 million of Series C Preferred equity in an oversubscribed round led by funds managed by Oaktree Capital Management, L.P. (“Oaktree”).
UserTesting Announces Pricing Of Initial Public Offering
UserTesting, Inc. (“UserTesting”), a leading provider of human insight, delivered through a video-first, experience testing platform, today announced the pricing of its initial public offering of 10,000,000 shares of common stock at a public offering price of $14.00 per share.
Prove Launches Game-Changing Onboarding Solution with KYC Included at No Additional Cost
Prove, the modern way for businesses to enable their customers to prove their identities with just a phone, announced today that its Prove Pre-Fill™ and other onboarding solutions now include Know Your Customer (KYC) and anti-money laundering (AML) checks, including sanctions, watchlists, and politically exposed persons (PEP) screening at no additional cost.